Reliability note

Titles and AI summaries are unofficial English monitoring aids, not legal advice or official translations. Each link opens the original Japanese official source, which remains authoritative.

PMDA announcement on nitrosamine detection in telmisartan products

テルミサルタン製剤におけるニトロソアミン化合物検出のお知らせを掲載しました

Published: 2026-11-05 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-11-06

View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard

AI summary

Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.

Summary

On 2026-11-05, the Pharmaceuticals and Medical Devices Agency announced the posting of information on nitrosamine compounds detected in telmisartan products. The supplied page lists detection notices for telmisartan tablets in 20 mg, 40 mg and 80 mg strengths under the Fersen, Sandoz and Meiji names; the excerpts do not establish contamination levels, affected batches or a telmisartan-specific recall. The page explains that the Ministry of Health, Labour and Welfare previously notified pharmaceutical marketing authorization holders to conduct nitrosamine contamination-risk self-inspections. The accompanying Q&A explains that the scope generally covers medicines containing synthetic or semi-synthetic active ingredients, with appropriate risk assessment also expected for other medicines. It also states that confirmed contamination above applicable limits following reassessment should be reported promptly to the Compliance and Narcotics Division, with risk-reduction measures and any necessary approval applications or notifications.

Business Impact

Marketing authorization holders for the listed telmisartan tablets may need to assess the product-specific detection notices against their quality-risk assessments and communications to medical institutions. Pharmaceutical marketing authorization holders more broadly may be affected by the existing self-inspection guidance; the excerpts do not establish a new requirement arising from this announcement.

Recommended Action

A review could check the individual Fersen, Sandoz and Meiji notices for measured levels, affected batches and any stated response measures. The accompanying Q&A could also be checked for how its reassessment, reporting and risk-reduction procedures apply to the relevant product.